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Abstract: Introduction: Pulmonary hypertension (PH) is a common complication in patients with
congenital heart disease (CHD), aggravating the natural, post-operative, or post-interventional course
of the underlying anomaly. The various CHDs differ substantially in characteristics, functionality, and
clinical outcomes among each other and compared with other diseases with pulmonary hypertension.
Objective: To describe current management strategies and outcomes for adults with PH in relation to
different types of CHD based on real-world data. Methods and results: COMPERA (Comparative,
Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension) is a prospective,
international PH registry comprising, at the time of data analysis, >8200 patients with various forms of
PH. Here, we analyzed a subgroup of 680 patients with PH due to CHD, who were included between
2007 and 2018 in 49 specialized centers for PH and/or CHD located in 11 European countries. At
enrollment, the patients’ median age was 44 years (67% female), and patients had either pre-tricuspid
shunts, post-tricuspid shunts, complex CHD, congenital left heart or aortic disease, or miscellaneous
other types of CHD. Upon inclusion, targeted therapies for pulmonary arterial hypertension (PAH)
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included endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, and soluble
guanylate cyclase stimulators. Eighty patients with Eisenmenger syndrome were treatment-naïve.
While at inclusion the primary PAH treatment for the cohort was monotherapy (70% of patients),
with 30% of the patients on combination therapy, after a median observation time of 45.3 months,
the number of patients on combination therapy had increased significantly, to 50%. The use of oral
anticoagulants or antiplatelets was dependent on the underlying diagnosis or comorbidities. In the
entire COMPERA-CHD cohort, after follow-up and receiving targeted PAH therapy (n = 511), 91
patients died over the course of a 5-year follow up. The 5-year Kaplan–Meier survival estimate for
CHD associated PH was significantly better than that for idiopathic PAH (76% vs. 54%; p < 0.001).
Within the CHD associated PH group, survival estimates differed particularly depending on the
underlying diagnosis and treatment status. Conclusions: In COMPERA-CHD, the overall survival of
patients with CHD associated PH was dependent on the underlying diagnosis and treatment status,
but was significantly better as than that for idiopathic PAH. Nevertheless, overall survival of patients
with PAH due to CHD was still markedly reduced compared with survival of patients with other
types of CHD, despite an increasing number of patients on PAH-targeted combination therapy.
Keywords: congenital heart disease; pulmonary hypertension; pulmonary arterial hypertension;
adults; observational; survival; targeted therapy
1. Introduction
Pulmonary hypertension (PH) is one of the most severe complications of congenital anomalies of
the heart and/or the great vessels (CHD) [1]. The presence of PH aggravates the natural, post-operative
or post-interventional course of the underlying anomaly and impacts disease burden and outcome.
The various types of CHD (i.e., pre-/post-tricuspid shunts, complex lesions) differ substantially in
disease, clinical manifestation, functionality, and clinical outcomes, and the prevalence, characteristics,
and impact of PH largely depend on the nature of the anomaly. However, scientific data on the impact
of PH on the various forms of CHD remain sparse.
According to current guidelines [2], PH is generally defined as a mean pulmonary artery pressure
(mPAP) ≥25 mmHg, although an even lower threshold of 20 mmHg has recently been proposed by
the Sixth World Symposium on Pulmonary Hypertension [3]. Pre-capillary PH, characterized by a
pulmonary artery wedge pressure (PAWP) ≤15 mmHg and a pulmonary vascular resistance (PVR)
>3 Wood units (WU), is distinguished from postcapillary PH, where PAWP is ≥15 mmHg, and PVR
may be <3 WU (isolated post-capillary) or ≥3 WU (combined post- and pre-capillary) [2,3]. The given
hemodynamic definitions also apply to PH associated with CHD [2].
The clinical classification of PH comprises five major groups: pulmonary arterial hypertension
(PAH, Group I); PH due to left heart disease (LHD, Group II); PH due to lung disease (Group III);
chronic thromboembolic PH (Group IV); and unclear or multifactorial PH (Group V) [4]. According to
guideline recommendations, PH associated with CHD is assigned to either Group I (PAH), Group II
(due to LHD), or Group V (unclear/multifactorial mechanism) [1,2,5–7].
The incidence of PH associated with CHD has been declining in developed countries but remains
prevalent despite advances in modern medicine. This is also true for Eisenmenger syndrome [6]. The
prevalence of PAH ranges from 4.2% to 28% in CHD patients, and Eisenmenger syndrome develops
in 3.5% to 7.1% of patients with CHD and PAH [8,9]. Women with CHD have a 33% higher risk
of developing PAH than men [10], which is consistent with the female predominance in idiopathic
PAH [11].
Due to the improved survival chances of both patients who have undergone successful repair
of a left-right shunt and complex patients with palliative Fontan circulation who may develop
non-Eisenmenger types of PH, clinical deterioration due to pulmonary vascular disease has become
J. Clin. Med. 2020, 9, 1456 5 of 21
a common complication. In the future, this complication is likely to increase, largely determining
morbidity and mortality of affected patients [6,12–16]. Beyond that, PH is also an evolving phenomenon
in aging patients with congenital anomalies of the left heart, e.g., in aortic coarctation, congenital aortic
valve disease, or congenital mitral valve disease [1].
Although numerous drugs have been approved for the treatment of PAH, the evidence for their
efficacy and safety in CHD remains limited, as these patients have either been excluded from major
trials or were underrepresented and inadequately characterized. Furthermore, reliable data on the
outcomes of patients with PAH in CHD is comparatively limited compared with data on patients with
idiopathic PAH.
The aim of the current study was to depict demographics, characteristics, treatment patterns,
and outcome of patients with PH due to CHD who were included into COMPERA (Comparative,
Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH
registry that enrolls patients with all forms of PH, and constitutes one of the largest series of patients
with any form of PH or pulmonary vascular disease [17–19].
2. Patients and Methods
2.1. Setting
The COMPERA registry was launched in July 2007 and continues to enroll patients [20]. Since
June 2009, COMPERA includes patients with all forms of PH on any pulmonary vasoactive therapy.
From June 1st, 2007 until December 1st, 2018, a total of 8200 adult PH patients have been registered
in COMPERA.
The registry was approved by the institutional review boards (Technical University Dresden,
Germany: Master approval EK 129052007 as of 22 May 2007) of all contributing centers and written
informed consent was obtained from all participating patients before the start of documentation.
Guidelines on good pharmacoepidemiological practice (GPP) and data protection guidelines were
followed. As of December 1st, 2018, 49 PAH centers from 11 European countries (Austria, Belgium,
Germany, Hungary, Italy, Latvia, Lithuania, Slovakia, Switzerland, the Netherlands, and the UK) had
entered their data in COMPERA-CHD.
2.2. Patient Selection
Included in the current study were adults (age ≥18 years) with any form of PAH in CHD on
targeted PAH-drug treatment for the PAH, either as mono- or combination therapy. In addition, the
registry allowed the documentation of patients with Eisenmenger physiology not receiving targeted
PAH treatment.
The PAH diagnosis was established by the participating investigators from expert centers
according to current guidelines [3,21], but was not adjudicated by a third party. Eisenmenger syndrome
was defined as PH associated with CHD stemming from an initially large, non-restrictive intra- or
extracardiac communication with systemic-to-pulmonary shunt, that induced progressive pulmonary
vascular disease, shunt reversal, and central cyanosis.
Also included and designated as “Non-Eisenmenger-PAH-treated” were CHD patients
who had undergone previous corrective surgery or interventions for an intra- or extracardiac
systemic-to-pulmonary shunt, with PAH associated with prevalent systemic-to-pulmonary shunts, or
PAH with small/coincidental defects.
Moreover, patients with univentricular circulation after cavo-pulmonary anastomosis (modified
Fontan operation) were documented if they received targeted PAH medication for “pulmonary vascular
disease or dysfunction”.
Targeted PAH medication included endothelin receptor antagonists (ERA), phosphodiesterase
type-5 inhibitors (PDE5i), riociguat (as the only licensed soluble guanylate cyclase (sGC) stimulator),
or prostanoids (including selexipag as an oral prostacyclin receptor agonist).
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2.3. Data Documentation
Patients were included on a consecutive basis with data collected prospectively at the time of
diagnosis (baseline), and usually in six-month intervals or whenever the patient had a predefined
clinical event (death, transplantation, PH-related hospitalization, deterioration in World Health
Organization (WHO) functional class (WHO-FC), any unscheduled change in PAH therapy, or other
serious adverse events).
Documentation included demographics (age, sex), type of PH according to the 2013 nice
classification, WHO-FC, six-minute walking distance (6MWD), selected laboratory variables,
hemodynamic data obtained by previous cardiac catheterization, arterial oxygen saturation, and
detailed information about the PAH medication [3].
For the documentation of adults with PAH due to CHD, the treatment centers were offered either
a standard internet-based documentation form or an extended documentation form for specialist
centers capturing additional information (i.e., type and repair status of cardiac malformation and
additional hemodynamic parameters). The collected, comprehensive data allowed the description and
categorization of subgroups of CHD in greater detail and with higher reliability than in previous reports.
Out-of-range data or missing values were automatically queried during data entry or in the context
of statistical plausibility checks at regular intervals. The validity of the entered data was verified by
comparison of registry data with source data in the patient files in the context of independent on-site
monitoring in approximately 70% of the participating centers.
In order to compare the findings on PAH in CHD patients with those in other PAH populations,
incident patients (inclusion within six months of diagnosis) with idiopathic PAH—according to
European Society of Cardiology (ESC) and the European Respiratory Society (ERS) guidelines—who
were enrolled into COMPERA after January 1st, 2009, were selected for comparison.
For CHD patients, time since inclusion into COMPERA was evaluated, for idiopathic PAH time
since diagnosis. Survival analyses were restricted to an observation time of 5 years.
2.4. Statistical Analysis
Descriptive statistics in terms of percentages, median with interquartile range (IQR), or mean with
standard deviations were provided to describe characteristics of the study population. Comparison
of categorical variables was conducted by the χ2-test or the Fisher’s exact test. Group differences of
continuous variables were tested with a t-test if normal distribution was assumed, or the Mann–Whitney
test otherwise. A p-value < 0.05 was considered significant. Survival was compared using Kaplan–Meier
analysis, and p-values of the Breslow test are shown. Tests were performed without adjustment for
multiple testing. IBM SPSS Statistics 24.0 (IBM, Armonk, NY, US) was used for all statistical analyses.
The author(s) of this manuscript have certified that they comply with the Principles of Ethical
Publishing in the American Journal of Cardiology [22].
3. Results
3.1. Patient Demographics and Baseline Characteristics
Out of 8200 adult PH patients enrolled in COMPERA at the time of data analysis, 680 (8.3%) had a
diagnosis of PAH due to CHD, and were therefore eligible for the present analysis.
Patient demographics and baseline characteristics are summarized in Tables 1–3. All patients
had undergone a complete non-invasive evaluation upon enrollment. Cardiac catheterization had
been performed in 487 patients (71.6%). In patients without catheterization, the PAH diagnosis was
established through non-invasive imaging and clinical evaluation.
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Table 1. Demographics and clinical characteristics at enrollment.
IPAH
(n = 1481)
PAH-CHD
Total
(n = 680)
ES
Untreated
(n = 80)
ES Treated
(n = 240)
Non-ES-PAH
Treated
(n = 167)
Fontan
Treated
(n = 7)
Age 66.3 ± 15.5 45.5 ± 16.8 40.1 ± 14.6 43.8 ± 15.1 47.6 ± 18.3 31.9 ± 9.4
Sex male 604 40.8% 227 33.4% 26 32.5% 76 31.7% 55 32.9% 3 42.9%
female 877 59.2% 453 66.6% 54 67.5% 164 68.3% 112 67.1% 4 57.1%
FC unknown 78 5.3% 80 11.8% 30 37.5% 19 7.9% 14 8.4% 4 57.1%
I 3 0.2% 22 3.2% 1 1.3% 8 3.3% 5 3.0% 0 0%
II 178 12.0% 159 23.4% 11 13.8% 65 27.1% 44 26.3% 3 42.9%
III 997 67.3% 392 57.6% 36 45.0% 136 56.7% 101 60.5% 0 0%
IV 225 15.2% 27 4.0% 2 2.5% 12 5.0% 3 1.8% 0 0%
6-min-walk
distance (m) 294 ± 123 367 ± 120 392 ± 118 354 ± 121 381 ± 120 475 ± 50
Abbreviations: CHD, congenital heart disease; ES, Eisenmenger syndrome; FC, functional class according to Perloff;
IPAH, idiopathic pulmonary arterial hypertension; non-ES-PAH, patients with congenital heart disease-associated
pulmonary arterial hypertension but without Eisenmenger syndrome; PAH-CHD; congenital heart disease-associated
pulmonary arterial hypertension. Age and 6-min-walk distance are given in mean ± SD.
Table 2. Treatment characteristics of the patients with congenital heart disease-associated pulmonary
arterial hypertension. “Non-Eisenmenger-PAH treated” comprises patients with congenital heart
disease-associated pulmonary arterial hypertension but without Eisenmenger syndrome who received
targeted PAH treatment. Abbreviations: PAH, pulmonary arterial hypertension.
Treatment Characteristics Number of Patients Included
CHD-PAH total 680
Eisenmenger - untreated 80 (11.8%)
Eisenmenger - treated 240 (35.3%)
Non-Eisenmenger-PAH - treated 167 (24.6%)
Fontan - treated 7 (1.0%)
Not categorized 186 (27.4%)
Targeted PAH medication
Endothelin receptor antagonists (ERA) 389 (57.2%)
Phosphodiesterase type-5 inhibitors (PDE5i) 353 (51.9%)
Prostanoids 35 (5.1%)
Soluble guanylate cyclase (sGC) stimulator 17 (2.5%)
Tyrosine kinase inhibitor 1 (0.1%)
Treatment strategy and supportive treatment
Monotherapy with targeted PAH medication 408 (60.0%)
Combination therapy with targeted PAH medication 192 (28.3%)
Oral anticoagulation: Vitamin K antagonists 217 (31.9%)
Oral anticoagulation: Non-vitamin K antagonists (NOAC) 30 (4.4%)
Antiplatelet therapy (Aspirin, Clopidogrel) 68 (10.0%)
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Table 3. Targeted PAH treatment of the patients with congenital heart disease-associated pulmonary
arterial hypertension. “Non-Eisenmenger-PAH treated” comprises patients with congenital heart
disease-associated pulmonary arterial hypertension but without Eisenmenger syndrome who received
targeted PAH treatment. Abbreviations: ERA, endothelin receptor antagonists; PAH, pulmonary
arterial hypertension; PDE5-I, phosphodiesterase type-5 inhibitors; sGC-stimulator, soluble guanylate
cyclase (sGC) stimulator. Comparative tests were only performed between treated Eisenmenger and
non-Eisenmenger patients.
Treatment
Group
Number of
Patients
Included (Total)
Targeted PAH
Medication n (%) p-Value
Mono-/
Combination-
Therapy
p-Value
CHD-associated
PAH - total 680
ERA
PDE5-I
Prostanoid
sGC-stimulator
Tyrosine kinase
inhibitor
389 (57.2%)
353 (51.9%)
35 (5.1%)
17 (2.5%)
1 (0.1%)
408 (60.0%)/
192 (28.3%)
Eisenmenger,
treated 240
ERA
PDE5-I
Prostanoid
sGC-stimulator
Tyrosine kinase
inhibitor
172 (71.7%)
134 (55.8%)
20 (8.3%)
7 (2.9%)
0
152 (63.3%)/
88 (36.7%)
Non-Eisenmenger-
PAH, treated 167
ERA
PDE5-I
Prostanoid
sGC-stimulator
Tyrosine kinase
inhibitor
100 (59.9%)
97 (58.1%)
7 (4.2%)
6 (3.6%)
1 (0.6%)
0.013
0.652
0.099
0.703
0.410
121 (72.5%)/
46 (27.5%) 0.054
Fontan, treated 7
ERA
PDE5-I
Prostanoid
sGC-stimulator
Tyrosine kinase
inhibitor
1 (14.3%)
7 (100 %)
1 (14.3%)
0
0
6 (85.7%)/
1 (14.3%)
Not categorized,
treated 187
ERA
PDE5-I
Prostanoid
sGC-stimulator
Tyrosine kinase
inhibitor
116 (62.4%)
115 (61.8%)
7 (3.8%)
4 (2.2%)
0
129 (69.4%)/
57 (30.6%)
In the entire cohort of 680 patients with CHD-associated PAH, 320 (47.1%) had a proven
Eisenmenger syndrome, 167 (24.6%) had “non-Eisenmenger PAH”, and 7 (1.0%) had a Fontan
circulation. Another 186 (27.4%) patients with CHD were on a targeted PAH medication but could not
be clearly categorized on the basis of the data entered.
The median age was 44 years (range 18–87 years), and 66.6% (n = 453) were female. More than
half of the patients were in the 3rd, 4th, or 5th decade of life (n = 379, 55.7%); 148 patients were younger
than 30 years (21.8%); and 153 patients (22.5%) were in the 6th decade of life or older (22.5%) (Figure 1).
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CHD, congenital heart disease.
At first assessment, 26.6% (n = 181), 57.6% (n = 392), and 4.0% (n = 27) of the patients were in
WHO-FC I/II, III, and IV, respectively. WHO-FC was not documented in 80 patients (11.8%). At the
time of inclusion, the mean 6MWD (assessed in 454 patients) was 367 ± 120 m.
3.2. Type of Congenital Heart Defect
The underlying main diagnoses of CHD were sub-classified into five groups (Table 4): pre-tricuspid
shunts (n = 213); post-tricuspid shunts (n = 325); complex forms of CHD (n = 121); left-sided heart
disease, congenital aortic valve anomalies and obstruction of the aorta (n = 9); and “other CHD”,
a group of 12 patients with diagnoses of pulmonary artery stenosis (n = 3), AV valve anomalies (n = 2),
and other entities (n = 5), as well as two patients for whom the type of CHD was not reported in detail.
Table 4. Subgroups of adult patients with PAH, and types of congenital heart defects.
n (%)
1. Pre-tricuspid shunts (n = 213)
Persisting foramen ovale 5 (0.7)
Atrial septal defect 186 (27.4)
Partial atrioventricular septal d fect 4 (0.6)
Partial anomalous pulmonary venous return 16 (2.4)
Total anomalous pulmonary venous return 1 (0.1)
details not stated 1 (0.1)
2. Post-tricuspid shunts (n = 325)
Complete atrioventricular sept l defect 79 (1 .6)
Ventricular septal defect 199 (29.3)
Patent ductus arteriosus Botalli 40 (5.9)
Aortopulmonary window 6 (0.9)
details not stated 1 (0.1)
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Table 4. Cont.
n (%)
3. Complex anomalies (n = 121)
Complete transposition of great arteries 19 (2.8)
Congenitally corrected transposition of great arteries 12 (1.8)
Double-outlet right ventricle with transposition of
great arteries 5 (0.7)
Truncus arteriosus 4 (0.6)
Tricuspid atresia 12 (1.8)
Double-inlet ventricle 13 (1.9)
Pulmonary atresia with intact ventricular septum 1 (0.1)
Fallot´s Tetralogy 13 (1.9)
Double-outlet right ventricle—Fallot type 9 (1.3)
Pulmonary atresia with ventricular septal defect 30 (4.4)
Ebstein’s anomaly 2 (0.3)
details not stated 1 (0.1)
4. Left heart disease/aortic valve,
and aortic anomalies (n = 9)
Aortic coarctation 2 (0.3)
Aortic valve stenosis 5 (0.7)
Subaortic stenosis 1 (0.1)
Aortic valve regurgitation 1 (0.1)
5. Other congenital cardiac
anomalies (n = 12)
Atrioventricular valve anomalies 2 (0.3)
other 5 (0.7)
Pulmonary artery stenosis 3 (0.4)
details not stated 2 (0.3)
The most common underlying CHD was ventricular septal defect (29.3%), followed by atrial
septal defect (27.4%), atrioventricular septal defect (11.6%), patent ductus arteriosus Botalli (5.9%), and
pulmonary atresia with ventricular septal defect (4.4%).
A total of 167 patients (63.3%) had developed PAH after previous reparative cardiac surgery for
CHD (operated; n = 264). For 55 of these patients (20.8%), the dates of PAH diagnosis and/or surgery
were not available.
Down syndrome was present in 92 patients and most of them had a complete atrioventricular-septal
defect (AVSD) (58.7%) or a ventricular septal defect (27.2%) as underlying CHD.
3.3. Medication and Treatment Strategy
At baseline, of the entire CHD-associated PAH group of 680 patients, 600 (88.2%) received targeted
PAH therapy. Of those 600 patients, 389 (65%) received endothelin receptor antagonists; 353 (59%)
phosphodiesterase type-5 inhibitors; 35 (5.8%) prostanoids; 17 (2.8%) a soluble guanylate cyclase
stimulator; a single patient a tyrosine kinase inhibitor; and 24 (4.0%) received calcium channel blockers
(Figure 2).
Phosphodiesterase type-5 inhibitors were the preferred drug class in the small Fontan cohort
(n = 7; 7/7 of these patients received this treatment).
Regarding baseline use within each drug class, among endothelin receptor antagonists, bosentan
(n = 276) was more often used than ambrisentan (n = 49), sitaxentan (n = 26), or macitentan (n = 38),
while among phosphodiesterase type-5 inhibitors (n = 353), sildenafil (n = 286) was more often used
than tadalafil (n = 67). With regard to sitaxentan, it should be noted that the registry was established at
a time when this drug had not yet been withdrawn from the market.
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Figure 2. Drug classes for targeted PAH therapy in the patients with CHD-associated PAH at inclusion
and at a t observation (mean/median observation time of 50.5/45.3 months respectivel for 512
patients with at least one f llow-up). “Other therapy” i l es soluble guanylate cyclase (sGC)
stimulator, tyrosine kinase inhibitor, calcium channel blockers, and other PAH-specific trial therapies.
Abbreviations: PCA, prostanoids.
Considering changes in targeted PAH medications over time, the primary treatment choice was
maintained in the majority of patients. Changes in drug prescription within the different drug classes
of targeted PAH therapy between inclusion and at last observation (median 45.3 months) are depicted
in Figure 2 for 512 patients with at least one follow-up.
Among all treated patient groups (n = 600), the primary treatment strategy at inclusion was
monotherapy in the majority of patients. In the Eisenmenger and non-Eisenmenger-PAH patients, 33%
and 27%, respectively, were on initial combination therapy with at least two PAH drugs. In the small
Fontan group (n = 7), all but one patient were on monotherapy.
During the observation period, the treatment pattern changed over time, as significantly more
patients were on combination therapy at their last observation (Figure 3).
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Figure 3. Targeted mono- or combination therapy in 512 CHD patients with PAH, with at least one
follow-up using different drug classes at inclusion and at last observation (mean/median observation time
of 50.5/45.3 months respectively). CHD, congenital heart disease; PAH, pulmonary arterial hypertension
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The use of anticoagulants or platelet inhibitors varied among groups, and according to the time of
observation. The use of anticoagulants or platelet inhibitors was lowest in untreated Eisenmenger
patients and highest in patients with Fontan circulation (Figure 4).
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Figure 4. Anticoagulation/platelet inhibition regime in patients with CHD-associated PAH at inclusion
and at last observation. Abbreviations: CHD, congenital heart disease; NOAC, non-vitamin K
antagonists; vit, vitamin; PAH, pulmonary arterial hypertension
3.4. Survival
The survival status of patients receiving PAH medication was evaluated in 511 patients of the
CHD cohort and 1326 patients from the idiopathic PAH cohort. Five-year survival could be ascertained
in 78% (400 out of 511) of the CHD-cohort and 66% (872 out of 1326) of the idiopathic PAH cohort. The
intermediate loss to follow-u was 3.9% (20 out of 511) in the CHD group, and 2.6% (35 out of 1326) in
the idiopathic PAH group.
In patients rec iving targeted PAH thera y at enrollment, 91 CHD patients and 419 idiopathic
PAH patients died during the 5-year follow-up period. Survival of CHD patients with targeted PAH
treatment was superior to that of idiopathic PAH patients; the 5-year (Kaplan–Meier) survival estimate
was 76% for CHD with PAH and 54% for idiopathic PAH (p < 0.001) (Figure 5A).
Within the entire CHD cohort that received targeted PAH therapy at enrollment, the 5-year
Kaplan–Meier survival estimate was 76% overall, 78% for Eisenmenger patients, and 77% for
non-Eisenmenger-PAH patients (p = 0.384) (Figure 5B). Thus, the non-Eisenmenger-PAH patients, had
5-year survival rates comparable to those of the Eisenm ger patients.
The current data show that the survival rate in Eisenmenger patients is also affected by the
complexity of the CHD. The sur ival rate f 121 patients with Eisenmenger syndrome due to a
complex CHD (including transposition of the great arteries, congenitally corrected transposition of the
great arteries, double-inlet ventricle, double-outlet right ventricle—Fallot type, double-outlet right
ventricle with transposition of the great arteries, Ebstein´s anomaly, tetralogy of Fallot, tricuspid
atresia, pulmonary atresia with intact ventricular septum, pulmonary atresia with ventricular septal
defect, and truncus arteriosus), was worse than the survival rate of patients in whom simple CHD
had caused an Eisenmenger syndrome. Among the Eisenmenger patients receiving targeted PAH
therapy at enrollment, nine pat nts in the co pl x-CHD and 23 patients in the simple-CHD cohort
died during the 5-year follow-up period. Survival of patients with Eisenmenger syndrome due to
a simple CHD was superior to survival of those with Eisenmenger syndrome caused by a complex
CHD; the 5-year Kaplan–Meier survival estimate was 81% for simple CHD and 64% for complex CHD
(p = 0.063) (Figure 5C).
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Figure 5. Kaplan–Meier 5-year survival estimates. (A) Comparison of all patients who underwent
targeted PAH treatment for either congenital heart dise se-associated pulmonary hypertension (CHD
treated, total) or incident idiopathic PAH. The 5-year Kaplan–Meier survival estimate was 76%
for PAH due to CHD and 54% for idiopathic PAH (p < 0.001). (B) Comparison of subgroups of
patients with CHD and PAH under targeted PAH medication: (1) CHD-treated, total (green); (2)
Eisenmenger-patients-treated (EM treated; purple); (3) non-Eisenmenger-PAH-patients (Non-EM
treated; blue). The overall 5-year survival estimate was 76%, compared with 78% for the Eisenmenger
patients, and 77% for the non-Eisenmenger-PAH-patients (p = 0.384). (C) Comparison of subgroups
of patients with Eisenmenger syndrome due to complex or simple CHD. The 5-year Kaplan–Meier
survival estimate was 81% for Eisenmenger syndrome caused by simple CHD and 64% for Eisenmenger
syndrome due to complex CHD (p = 0.063). Kaplan–Meier survival estimates (top) and number of
cases still under observation (bottom) are shown in tabular form. Abbreviations: CHD, congenital
heart disease; non-EM, non-Eisenmenger-PAH-patients; PAH, pulmonary arterial hypertension.
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4. Discussion
The international COMPERA-CHD registry provides information on the characteristics, treatment
patterns, and long-term outcomes in a large number of patients with PAH caused by CHD, in the
modern treatment era. This is of paramount importance as there are relatively limited data on targeted
PAH therapy and outcomes in adults with PAH resulting from CHD compared with idiopathic
PAH [1,23–27]. Furthermore, the existing data are mostly derived from small, uncontrolled studies with
few patients, predominantly with simple congenital heart defects, and short monitoring periods [28].
Evidence for the efficacy, safety, and tolerability of PAH therapies (endothelin receptor antagonists,
phosphodiesterase type-5 inhibitors/soluble guanylate cyclase stimulators, prostanoids) is available
from numerous randomized clinical trials of acquired PAH, demonstrating improvements in exercise
tolerance, quality of life, and reduction of morbidity and mortality events in PAH [29–32]. However,
such data may be ambiguous or even misleading for the management of PAH in CHD.
Even if patients with CHD and PAH were included in the majority of trials, neither the type of
CHD nor the CHD-specific hemodynamic status have been sufficiently considered, and data have not,
for the most part, been presented separately from data on non-congenital forms of PAH.
Accordingly, there is a shortage of evidence about targeted PAH therapies for CHD with PAH,
and it remains unclear whether data from current studies on other forms of PAH can be applied to
PAH patients with CHD [23,33].
As long as data from randomized controlled trials are not available for PAH from CHD, data from
registries, which include larger patient populations and longer observation periods than clinical trials,
are valuable to characterize PAH associated with CHD in terms of demographics, clinical presentation,
risk factors, and outcomes, as well as PAH-targeted therapies or supportive measures. However,
similar to controlled clinical trials, most PAH registries have so far also failed to differentiate between
CHD subtypes, and have merged the characteristics, treatments, and outcomes of different patient
groups, thus precluding the analysis of details on CHD subgroups [12,13,34–38].
Accordingly, the special situation of CHD patients is not yet adequately addressed in the current
PAH guidelines. The German consensus-based recommendations for the management of patients with
pulmonary hypertension state that the ESC/ERS guidelines on pharmacotherapy in PAH from CHD
are focused on patients with Eisenmenger syndrome. The main reason for this may be the currently
available evidence, but this also implies that the recommendations do not fully acknowledge the
breadth, heterogeneity, and complexity of CHD patients with associated PAH [1]. The COMPERA
registry provides for the first time such data in Europe on a broad scale.
The COMPERA registry is one of the largest structured, non-interventional (observational),
prospective international registries for patients with any form of PH, providing a unique opportunity to
obtain detailed information on epidemiological and clinical features, treatment patterns, and outcomes
in a sufficient number of patients with various forms of CHD with PAH. Within this registry, we
analyzed a group of 680 adults with CHD and PAH, with a focus on PAH-targeted therapy, supportive
treatment, and outcome. As a unique feature, COMPERA-CHD not only included adults with CHD
associated PAH who were receiving PAH-targeted therapy, but also a number of Eisenmenger patients
who were not receiving any targeted therapy.
4.1. Demographics, Hemodynamics, and Treatment
This cohort of patients with CHD associated PAH comprised almost all types of congenital heart
anomalies, including post-tricuspid shunts (n = 325), followed by pre-tricuspid shunts (n = 213), and
complex anomalies (n = 121).
The mean age of each subgroup of patients with CHD associated PAH at the time of inclusion
was significantly lower than the mean age of the included idiopathic PAH patients, but higher than the
mean age in any other registry of patients with PAH in CHD [12,13,34–37].
Despite many parallels between PAH in CHD and idiopathic PAH, COMPERA revealed
several attributes that, depending on the underlying congenital cardiovascular anomaly, distinguish
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CHD-associated PAH from idiopathic PAH. These include a more favorable hemodynamic profile
due to a better maintenance of cardiac output and a more favorable right ventricular response, in
CHD-associated PAH [8].
One major difference is that, compared with other forms of PAH, the cause of PAH in CHD is often
multifactorial, but commonly secondary to a left-to-right shunt lesion leading to increased pulmonary
artery flow and/or pressure. Other important predisposing factors for pulmonary vascular disease in
CHD include previous Fontan operation and left heart obstructive disease causing post-capillary PH.
A further distinction from other forms of PAH is that, in CHD, timing and extent of the development
of PAH depends on various different factors, e.g., the pre- or post-tricuspid localization of the primary
left-to right shunt [39]. For example, Eisenmenger syndrome will evolve even in large defects at the
atrial level much later in life compared with defects at the ventricular or great artery levels.
Moreover, the data from the COMPERA registry confirm the perception that patients with PAH
from CHD, unlike patients with other forms of PAH, are often clinically stable for years or decades and
remain at a low WHO-FC until an advanced age.
This may explain why, despite the existence of Eisenmenger syndrome, a considerable number
of patients without PAH-targeted therapy enrolled in COMPERA. Pertinent to this, patients in the
untreated Eisenmenger cohort were younger and had milder clinical symptoms. In addition, in this
group, the 6MWD was substantially higher than that in treated Eisenmenger patients (392 ± 118 vs.
354 ± 121 m). These observations may indicate that healthcare centers did not apply targeted PAH
therapy indiscriminately but followed the current guidelines, which recommend PAH-targeted therapy
depending on clinical symptoms and WHO-FC.
In contrast, however, due to the accumulating evidence for the safety and efficacy of targeted
therapy, the majority of patients with CHD and PAH included in COMPERA were treated with targeted
PAH medications.
Among the various drug classes, at baseline, endothelin receptor antagonists and
phosphodiesterase type-5 inhibitors were by far the predominantly prescribed compounds, whereas
prostanoids and soluble guanylate cyclase stimulators were only rarely used.
Initially, the majority of the 600 treated patients with CHD associated PAH were on monotherapy,
although a significant number of patients was put on combination therapy (Figure 3). Furthermore,
utilization of combination therapy increased over time (with the exception of Fontan patients), with
approximately half of the patients being on combination therapy at the time of last observation
(Figure 3).
At that point, the therapeutic approach for adults with PAH and CHD differs from the approach
for those with idiopathic PAH, as there are only few data to support routine up-front/early sequential
oral combination therapy for Eisenmenger syndrome [1,6,26,39–42]. In adults with PAH and CHD,
sequential combination therapy is frequently initiated only upon symptomatic deterioration or if
predefined, and often center-specific treatment goals are not achieved [43].
4.2. Co-Medication with Anticoagulants or Antiplatelets
Another important subject is the use of oral anticoagulants or antiplatelets in CHD-associated
PAH, which appears to differ from that in idiopathic PAH [14]. A recent, controversially debated
study from the COMPERA group revealed a survival benefit from using anticoagulation in patients
with idiopathic PAH; however, for other forms of PAH, the evidence remained inconclusive [18]. In
patients with Eisenmenger syndrome, the situation is even more complex, as they usually have both
increased bleeding and increased thrombotic risk due to changes in platelet function, platelet counts,
and coagulation parameters. So far, no data exist suggesting that oral anticoagulation has a beneficial
effect on morbidity or mortality in Eisenmenger patients. Consequently, current guidelines on CHD do
not recommend the routine use of oral anticoagulation for these patients [1,6,44,45].
This approach is also reflected in the COMPERA data. At baseline, most patients (up to 66%)
in both subgroup with the Eisenmenger syndrome and the non-Eisenmenger-PAH subgroups were
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not anticoagulated using vitamin K antagonists, and only a few patients received oral non-vitamin
K antagonists.
In contrast, most patients with Fontan circulation (71%) were on oral anticoagulants to prevent
thromboembolic events, reflecting the common treatment strategy, at least in many adults with early
modifications of the Fontan operation [46].
Surprisingly, at least 13.4% of the Eisenmenger patients were on antiplatelets, although currently
no reliable data exist on a protective effect of Aspirin or Clopidogrel for this condition. The application
of antiplatelets can perhaps be attributed to the unproven belief that they may have fewer negative
effects on the bleeding tendency in cyanotic patients than oral anticoagulants. On the contrary, the
inhibitory effect of the always diminished count of platelets in cyanotic patients can be devastating.
4.3. Survival
Although mortality has decreased in adults with CHD, morbidity is still high due to residua,
sequelae, or complications, and many patients develop pathologies of the pulmonary vascular bed,
complicating the natural history of the particular anomaly [4,23,47,48]. In adults with PAH from
CHD, all-cause mortality is more than two-fold, and the rate of health service utilization is three-fold
higher compared with CHD without PAH [38]. Moreover, the survival prospects of treatment-naïve
patients with Eisenmenger syndrome has not improved since the 1960s, if confounding factors, such as
immortal time bias, are considered [49].
The survival rates of patients with different types of PAH have been published based on a
few studies and national registries, demonstrating that patients with PAH in CHD had a better
survival rate than those with idiopathic PAH. The current data from the COMPERA registry confirm
this, as the 5-year survival of patients with PAH from CHD was significantly better than that of
idiopathic PAH-patients.
It is noteworthy that the 5-year survival rate of treated patients with PAH from CHD in COMPERA
was 76%, i.e., lower than in some previous studies. However, Diller et al. recently reported a similar
5-year survival rate of 74.9% (95% CI 67.6–83.1%) for the Eisenmenger patients in the German National
Registry for CHD [24]. In contrast, Manes et al. showed, in their mono-centric analysis, estimated
survival rates of 87%, 86%, and 36% after follow-up for up to 20 years in 192 patients with Eisenmenger
syndrome, PAH in prevalent systemico-pulmonary shunts, and PAH after repair, respectively [42].
The unfavorable survival rate in COMPERA may be attributable to the fact that the PAH in several
of the enrolled patients was due to a complication of complex CHD (n = 121; 18%). In support of this
possibility, Diller et al. reported that patients with Eisenmenger syndrome due to complex CHD had a
significantly worse prognosis than patients with a simple CHD [50].
Comparing COMPERA CHD patients treated for Eisenmenger syndrome with those who had any
form of PAH from CHD but no Eisenmenger syndrome, there was no significant difference between
the groups in terms of 5-year survival.
Under targeted PAH medication, the survival rate of non-Eisenmenger-PAH patients appears to
be less favorable than that of Eisenmenger patients, especially over a time period of 1 to 4 years.
These data are in accordance with the results from the Spanish REHAP registry [12], as well as
data from Thailand [25]. Both of these studies also found that patients with Eisenmenger syndrome
had a better survival rate than patients with PAH after previous defect closure [12,25].
4.4. Limitations
Strengths include the large sample size of prospectively enrolled patients with PAH caused by
CHD, the inclusion of all types of PAH from CHD, the “real-life” setting, and the relatively long
observation period.
This study has limitations, as it is a voluntary, prospective registry and not a prospective
randomized clinical trial. However, COMPERA enrolls consecutive patients on a prospective basis and
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several control measures have been implemented to ensure high data quality, including independent
on-site source data monitoring. Still, missing values were a relevant limitation of this study.
Observational data such as ours are prone to various types of bias including selection bias,
incomplete outcome bias (attrition bias), immortal time bias, and survivor bias [51–53].
Statistical measures to reduce confounding factors, such as propensity score matching or
multivariable risk-adjusted modelling, were not applied, and therefore group differences at baseline
have to be considered for all results and conclusions.
COMPERA did not document in detail medications other than PAH-approved drugs and
anticoagulants, and did not determine therapeutic adherence, which is considered an integral
component of pharmaceutical care practice and patient healthcare.
As idiopathic PAH patients in the present series were older than patients in previous PH registries,
it cannot be excluded that some patients diagnosed with idiopathic PAH had comorbidities or
confounding factors that may have led to a mixed etiology of PH. However, all participating centers
had expertise in the management of PH and evaluated their patients according to the current guidelines.
Moreover, a similar trend regarding the age of idiopathic PAH patients has been reported from other
PH registries [54,55]. Co-morbidities were only assessed at inclusion in COMPERA and their increasing
presence at follow up might have affected survival.
Finally, the sample of patients may not represent the pattern of adults with PAH in the community
and does not represent the typical population of CHD seen by a general practitioner or a non-CHD
expert cardiologist.
5. Conclusions
PAH is still a serious problem for numerous patients with CHD and there are many uncertainties
regarding optimal medical treatment. In the future, it is expected that an increasing number of patients
will develop PAH with complex CHD or pulmonary vascular diseases in the univentricular heart after
a Fontan operation. The current data confirm the still-unfavorable prognosis and reduced survival
rates of patients with PAH from CHD, despite the availability of a variety of PAH-targeted drugs,
application modalities (e.g., oral, inhaled, subcutaneous, intravenous) and therapeutic strategies (e.g.,
mono, dual, or triple therapy), and palliative interventions (e.g., percutaneous Pott´s shunt).
The estimated survival rates for patients with CHD associated PAH at 5 years was only 76%, but
was nevertheless significantly better than those for idiopathic PAH patients. The best survival rate was
seen in patients with Eisenmenger syndrome.
The results of this study imply that it must be ascertained in any case, that the particularities
of CHD are taken into account in diagnosis and treatment, as the management of PAH-CHD is
often different from other forms of PAH. Accordingly, such patients should always be managed with
cooperation between CHD specialists and PAH specialists, preferably in tertiary care settings.
In the future, the registry will provide data on specific patient cohorts for PAH-CHD-targeted
therapeutic approaches and allow detailed survival analysis of these patients.
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